Mariana Rebordão-Pires, Marta F Estrada, António Gomes, Filipa Silva, Carlota Baptista, Maria João Ramos, Ana Fortuna, Pedro Simões, Gabriela Sousa, Ana Marreiros, Rita Fior
(1) Background: Relapsed HGSOC with ascites and/or pleural effusion is a poor-prognostic population and poorly represented in clinical studies. We questioned if these patients are worth treating. In other words, if these patients received the most effective treatment, would it change the course of this disease? To our knowledge this is the first real-life study to evaluate this question in this low-survival population. (2) Methods: To tackle this question we performed a retrospective, multi-centric, real-life study, that reviewed relapsed HGSOC patients with ascites and/or pleural effusion...
December 28, 2023: Cancers